Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical N

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms, Date of authorisation: 17/08/2022, Revision: 4, Status: Authorised